Guillaume AssiÃ©

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2198299/publications.pdf

Version: 2024-02-01

20 papers	2,823 citations	516710 16 h-index	794594 19 g-index
20 all docs	20 docs citations	20 times ranked	3437 citing authors

#	Article	IF	Citations
1	KDM1A inactivation causes hereditary food-dependent Cushing syndrome. Genetics in Medicine, 2022, 24, 374-383.	2.4	27
2	Corticotroph tumor progression after bilateral adrenalectomy (Nelsonâ€™s syndrome): systematic review and expert consensus recommendations. European Journal of Endocrinology, 2021, 184, P1-P16.	3.7	32
3	Somatotroph Tumors and the Epigenetic Status of the GNAS Locus. International Journal of Molecular Sciences, 2021, 22, 7570.	4.1	6
4	Pangenomic Classification of Pituitary Neuroendocrine Tumors. Cancer Cell, 2020, 37, 123-134.e5.	16.8	186
5	Glucocorticoid Excess in Patients with Pheochromocytoma Compared with Paraganglioma and Other Forms of Hypertension. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3374-e3383.	3.6	17
6	SUN-LB97 Targeted Metabolomics as a Screening Tool in the Diagnosis of Endocrine Hypertension. Journal of the Endocrine Society, 2020, 4, .	0.2	0
7	Genomics of benign adrenocortical tumors. Journal of Steroid Biochemistry and Molecular Biology, 2019, 193, 105414.	2.5	15
8	European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. European Journal of Endocrinology, 2018, 179, G1-G46.	3.7	559
9	Somatic USP8 mutations are frequent events in corticotroph tumor progression causing Nelsonâ€™s tumor. European Journal of Endocrinology, 2018, 178, 57-63.	3.7	37
10	Calling Chromosome Alterations, DNA Methylation Statuses, and Mutations in Tumors by Simple Targeted Next-Generation Sequencing. Journal of Molecular Diagnostics, 2017, 19, 776-787.	2.8	7
11	Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell, 2016, 29, 723-736.	16.8	482
12	Serum RARRES2 Is a Prognostic Marker in Patients With Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3345-3352.	3.6	21
13	Genetic Landscape of Sporadic Unilateral Adrenocortical Adenomas Without PRKACA p.Leu206Arg Mutation. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3526-3538.	3.6	65
14	Biological and radiological exploration and management of non-functioning pituitary adenoma. Annales D'Endocrinologie, 2015, 76, 201-209.	1.4	25
15	The 'omics' of adrenocortical tumours for personalized medicine. Nature Reviews Endocrinology, 2014, 10, 215-228.	9.6	41
16	Integrated genomic characterization of adrenocortical carcinoma. Nature Genetics, 2014, 46, 607-612.	21.4	560
17	Aberrant DNA hypermethylation of SDHC: a novel mechanism of tumor development in Carney triad. Endocrine-Related Cancer, 2014, 21, 567-577.	3.1	161
18	ARMC5Mutations in Macronodular Adrenal Hyperplasia with Cushing's Syndrome. New England Journal of Medicine, 2013, 369, 2105-2114.	27.0	319

#	Article	IF	Citations
19	The pathophysiology, diagnosis and prognosis of adrenocortical tumors revisited by transcriptome analyses. Trends in Endocrinology and Metabolism, 2010, 21, 325-334.	7.1	42
20	Corticotroph Tumor Progression after Adrenalectomy in Cushingâ€™s Disease: A Reappraisal of Nelsonâ€™s Syndrome. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 172-179.	3.6	221